| Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome | 06/28 08:00 | globenewswire.com |
| Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 06/24 17:18 | globenewswire.com |
| SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) and Encourages Long-Term Investors to Contact the Firm | 06/11 13:00 | accesswire.com |
| 3 Stocks That Have Seen Higher Share Gains Than Super Micro Computer | 06/06 16:18 | 247wallst.com |
| Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 | 05/22 16:05 | globenewswire.com |
| Soleno Therapeutics to Participate in Upcoming Investor Conferences | 05/22 08:00 | globenewswire.com |
| Soleno Therapeutics Stands with the Prader-Willi Syndrome Community | 05/15 08:00 | globenewswire.com |
| Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results | 05/09 16:05 | globenewswire.com |
| Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock | 05/02 22:32 | globenewswire.com |
| Soleno Therapeutics Announces Proposed Public Offering of Common Stock | 05/02 16:01 | globenewswire.com |